Journal article
Peroxiredoxin1 Prevents Excessive Endothelial Activation and Early Atherosclerosis
Circulation research, Vol.103(6), pp.598-605
2008
DOI: 10.1161/CIRCRESAHA.108.174870
PMCID: PMC4911701
PMID: 18689572
Abstract
The peroxiredoxin (Prdx) family of antioxidant enzymes uses redox-active cysteines to reduce peroxides, lipid hydroperoxides, and peroxynitrites. Prdx1 is known to be important to protect red blood cells against reactive oxygen species and in tumor prevention. In this study, the role of Prdx1 in inflammation, thrombosis, and atherosclerosis was investigated. Using intravital microscopy, we showed that the number of leukocytes rolling per minute in unstimulated veins was increased by 2.5-fold in Prdx1(-/-) compared to Prdx1(+/+) mice. In Prdx1(-/-) mice, 50% of leukocytes rolled at a velocity <10 mum/sec compared with 10% in Prdx1(+/+) mice, suggesting that adhesion molecule density on the endothelium may have been increased by Prdx1 deficiency. Indeed, endothelial P-selectin, soluble P-selectin, and von Willebrand factor in plasma were increased in Prdx1(-/-) mice compared to Prdx1(+/+) mice, indicating elevated Weibel-Palade body release. In contrast to this excessive endothelial activation, Prdx1(-/-) platelets showed no sign of hyperreactivity, and their aggregation both in vitro and in vivo was normal. We also examined the role of Prdx1 in the apoE(-/-) murine spontaneous model of atherosclerosis. Prdx1(-/-)/apoE(-/-) mice fed normal chow developed larger, more macrophage-rich aortic sinus lesions than Prdx1(+/+)/apoE(-/-) mice, despite similar amounts and size distributions of cholesterol in their plasma lipoproteins. Thus, Prdx1 protects against excessive endothelial activation and atherosclerosis, and the Prdx1(-/-) mice could serve as an animal model susceptible to chronic inflammation.
Details
- Title: Subtitle
- Peroxiredoxin1 Prevents Excessive Endothelial Activation and Early Atherosclerosis
- Creators
- Janka KISUCKA - Immune Disease Institute Inc, Harvard Medical School, Boston, Mass, United StatesAnil K CHAUHAN - Immune Disease Institute Inc, Harvard Medical School, Boston, Mass, United StatesIan S PATTEN - Immune Disease Institute Inc, Harvard Medical School, Boston, Mass, United StatesAyce YESILALTAY - Department of Biology Massachusetts Institute of Technology, Cambridge, Mass, United StatesCarola NEUMANN - Medical University of South Carolina Cell and Molecular Pharmacology, Charleston, United StatesRichard A VAN ETTEN - Molecular Oncology Research Institute Tufts-New England Medical Center, Boston, Mass, United StatesMonty KRIEGER - Department of Biology Massachusetts Institute of Technology, Cambridge, Mass, United StatesDenisa D WAGNER - Immune Disease Institute Inc, Harvard Medical School, Boston, Mass, United States
- Resource Type
- Journal article
- Publication Details
- Circulation research, Vol.103(6), pp.598-605
- DOI
- 10.1161/CIRCRESAHA.108.174870
- PMID
- 18689572
- PMCID
- PMC4911701
- NLM abbreviation
- Circ Res
- ISSN
- 0009-7330
- eISSN
- 1524-4571
- Publisher
- Lippincott
- Language
- English
- Date published
- 2008
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094554302771
Metrics
15 Record Views